- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-MLH1
MLH1 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain et plus (2)
Applications
WB, IHC, IF/ICC, IP, CoIP, ELISA
Conjugaison
Non conjugué
N° de cat : 11697-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules Caco-2, cellules HEK-293, cellules HeLa |
| Résultats positifs en IP | cellules HeLa, |
| Résultats positifs en IHC | tissu de cancer du côlon humain, il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
| Résultats positifs en IF/ICC | cellules HeLa |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:10000 |
| Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochimie (IHC) | IHC : 1:200-1:800 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 2 publications below |
| WB | See 17 publications below |
| IHC | See 13 publications below |
| IF | See 8 publications below |
| CoIP | See 1 publications below |
Informations sur le produit
11697-1-AP cible MLH1 dans les applications de WB, IHC, IF/ICC, IP, CoIP, ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | Humain, poisson-zèbre, souris |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Polyclonal |
| Type | Anticorps |
| Immunogène | MLH1 Protéine recombinante Ag2319 |
| Nom complet | mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
| Masse moléculaire calculée | 756 aa, 85 kDa |
| Poids moléculaire observé | 85 kDa |
| Numéro d’acquisition GenBank | BC006850 |
| Symbole du gène | MLH1 |
| Identification du gène (NCBI) | 4292 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par affinité contre l'antigène |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
MLH1, also named as COCA2, belongs to the DNA mismatch repair mutL/hexB family. It heterodimerizes with PMS2 to form MutL alpha which is a component of the post-replicative DNA mismatch repair system (MMR). MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. MLH1 also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. MLH1 heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.(PMID: 16873062, PMID: 18206974) Defects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2 (HNPCC2). Defects in MLH1 are a cause of mismatch repair cancer syndrome (MMRCS). Defects in MLH1 are a cause of Muir-Torre syndrome (MTS). Defects in MLH1 are a cause of susceptibility to endometrial cancer. Western blot analysis with an MLH1 antibody detected a 85-100 kDa band. Full-length human MLH1 is specifically cleaved into degradation products of 40-45 kDa by caspase-3 (PMID: 15087450, PMID: 19603033). This antibody is specific to MLH1.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for MLH1 antibody 11697-1-AP | Download protocol |
| IHC protocol for MLH1 antibody 11697-1-AP | Download protocol |
| IF protocol for MLH1 antibody 11697-1-AP | Download protocol |
| IP protocol for MLH1 antibody 11697-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cell Metab Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer | ||
Nucleic Acids Res NAT10-mediated N4-acetylcytidine modification is required for meiosis entry and progression in male germ cells. | ||
Nucleic Acids Res Prpf31 is essential for the survival and differentiation of retinal progenitor cells by modulating alternative splicing. | ||
J Hematol Oncol Integrated proteogenomic characterization of urothelial carcinoma of the bladder. | ||
Nucleic Acids Res Selective tumor cell death induced by irradiated riboflavin through recognizing DNA G-T mismatch. | ||
Cancer Lett Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination |
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
FH Elena (Verified Customer) (06-26-2025) | Works for us for IP
|
FH Manohar (Verified Customer) (12-18-2021) | No non-specific binding, blocked with milk for 1 hour and antibody incubation at 4degrees over night
|






